Omega Liquidating, Inc., formerly Omega Therapeutics, Inc., was a clinical-stage biotechnology company, which was engaged in the development of a programmable epigenomic mRNA medicine to treat or cure a broad range of diseases. The Company has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code. The Company remains in possession of its assets and continues to operate its business as a debtor in possession.

Employees

Sector

Investment Holding Companies

More about the company

Income Statement and Estimates

More financial data

Market Closed - OTC Markets Other stock markets 10:31:48 2025-08-08 EDT			5-day change	1st Jan Change
0.003000 ^USD	+50.00%		-.--%	-

25-08-08	Omega Therapeutics, Inc. Went Out of Business	CI
25-07-31	Revised Combined Liquidation Plan and Disclosure Statement Approved for Omega Therapeutics, Inc.	CI

Market Cap	41.28M 36.2M 33.36M 31.24M 58.57M 3.89B 59.79M 401M 155M 1.92B 155M 152M 6.67B	P/E 2022	-2.66x	P/E 2023	-1.67x
Enterprise Value	96.28M 84.42M 77.81M 72.85M 137M 9.08B 139M 935M 362M 4.49B 362M 354M 15.56B	EV / Sales 2022	83,097,425x	EV / Sales 2023	71,420,793x
Free-Float	98.38%	Yield 2022 *	-	Yield 2023	-

25-08-08	Omega Therapeutics, Inc. Went Out of Business	CI
25-07-31	Revised Combined Liquidation Plan and Disclosure Statement Approved for Omega Therapeutics, Inc.	CI
25-07-07	First Motion for Exclusivity Period Extension Approved For Omega Therapeutics, Inc.	CI
25-06-13	Modified Disclosure Statement and Liquidation Plan Approved on an Interim Basis for Omega Therapeutics, Inc.	CI
25-06-09	First Motion for Exclusivity Period Extension Filed by Omega Therapeutics, Inc.	CI
25-05-27	Combined Liquidation Plan and Disclosure Statement Filed by Omega Therapeutics, Inc.	CI
25-04-25	Revised Stalking Horse APA	CI
25-04-23	Motion for Asset Sale Filed by Omega Therapeutics, Inc.	CI
25-04-04	Notice of Cancellation of auction	CI
25-03-12	Bidding Procedure Approved for Omega Therapeutics, Inc.	CI
25-03-12	Final DIP Financing Approved for Omega Therapeutics, Inc.	CI
25-02-23	Omega Therapeutics, Inc.(OTCPK:OMGA.Q) dropped from NASDAQ Composite Index	CI
25-02-23	Omega Therapeutics, Inc.(NasdaqGS:OMGA) dropped from S&P TMI Index	CI

24-11-15	Raymond James Downgrades Omega Therapeutics to Market Perform From Outperform	MT
24-08-07	Chardan Adjusts Price Target on Omega Therapeutics to $7 From $6, Maintains Buy Rating	MT
24-06-18	Raymond James Initiates Omega Therapeutics at Outperform Rating With $12 Price Target	MT
24-04-03	Piper Sandler Trims Price Target on Omega Therapeutics to $9 From $10, Maintains Overweight Rating	MT
24-04-01	Chardan Cuts Price Target on Omega Therapeutics to $7 From $12, Keeps Buy Rating	MT

OMEA THER Stock

Stocks

OMGA

US68217N1054

Investment Holding Companies

Valuation: OMEA THER

Chart: OMEA THER

Latest news : OMEA THER

Analysts' recommendations: OMEA THER

Press Releases: OMEA THER

News in other languages: OMEA THER

Quotes and Performance

Course Extremes

Managers and Directors: OMEA THER

Latest insider transactions

Shell Companies

Financials

Company Profile

Income Statement and Estimates

24-11-21	Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies	AQ
24-11-14	Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results	GL
24-10-15	Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings	AQ
24-10-15	Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings	GL
24-09-27	Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry	AQ

24-01-04	Novo Nordisk signe des partenariats de recherche avec des biotechs américaines
24-01-04	Novo Nordisk : accords de recherche avec Omega et Cellarity

Manager	Title	Age	Since
Kaan Certel CEO	Chief Executive Officer	56	2024-11-13
Barbara Chan DFI	Director of Finance/CFO	62	2024-05-30
Jennifer Nelson CTO	Chief Tech/Sci/R&D Officer	-	2024-08-13

Director	Title	Age	Since
Elliott Levy BRD	Director/Board Member	67	2021-02-28
Rainer Boehm BRD	Director/Board Member	65	2022-08-31
Kaan Certel BRD	Director/Board Member	56	2024-11-13

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-12-02	Ravi Mehrotra	Free	Director	50,000	0.0903%
24-11-21	Jennifer Nelson	Other	Chief Technology Officer	110,000	0.1994%
24-11-21	Jennifer Nelson	Free	Chief Technology Officer	110,000	0.1994%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OMEA THER	+50.00%	-.--%	-92.46%	-99.95%	166K
EINRIDE AB	+17.31%	-9.42%	-	-	1.07B
CENTIEL AG	-9.46%	-6.81%	+375.19%	-61.51%	773M
CHURCHILL CAPITAL CORP XI	+11.41%	+34.50%	-	-	772M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	-0.20%	-0.50%	-	-	640M
BAIN CAPITAL GSS INVESTMENT CORP.	-0.10%	+0.59%	-	-	600M
CANTOR EQUITY PARTNERS IV, INC.	-0.15%	-0.25%	-	-	592M
CHURCHILL CAPITAL CORP XII	+0.48%	+3.88%	-	-	586M
KEYSTONE ACQUISITION CORP.	-0.10%	0.00%	-	-	580M
Average	+7.69%	-6.82%	+141.36%	-80.73%	623.48M
Weighted average by Cap.	+3.55%	+2.40%	+375.09%	-61.52%

	2022	2023
Net sales	2.07 1.82 1.68 1.57 2.94 195.55 3 20.14 7.79 96.65 7.78 7.61 335.13	3.09 2.71 2.5 2.34 4.39 291.86 4.48 30.06 11.63 144.25 11.62 11.36 500.18
Net income	-103M -90.05M -83M -77.71M -146M -9.69B -149M -998M -386M -4.79B -386M -377M -16.6B	-97.43M -85.42M -78.74M -73.72M -138M -9.19B -141M -946M -366M -4.54B -366M -358M -15.75B
Net Debt	-102M -89.52M -82.52M -77.25M -145M -9.63B -148M -992M -384M -4.76B -383M -375M -16.51B	55M 48.22M 44.45M 41.61M 78.03M 5.19B 79.66M 534M 207M 2.56B 207M 202M 8.89B

1 year	0		0.13
3 years	0		6.3
5 years	0		31.41
10 years	0		31.41